Innovating Works

CRISPRCINIMM

Financiado
Revealing genes that mediate the CIN-induced interferon-inflammatory response us...
Revealing genes that mediate the CIN-induced interferon-inflammatory response using a Genome-wide CRISPR screen coupled to a Suicide Gene Switch. Chromosomal instability (CIN) and the resulting aneuploidies can fuel the dramatic karyotype changes characteristic of tumorigenesis, helping tumors to alter the expression of immune checkpoints and evolving phenotypes related to... Chromosomal instability (CIN) and the resulting aneuploidies can fuel the dramatic karyotype changes characteristic of tumorigenesis, helping tumors to alter the expression of immune checkpoints and evolving phenotypes related to immune evasion or stimulation. Anti-tumor immunity appears to be dependent on the type and origin of the tumor, while immune evasion has become an obstacle to designing effective anticancer therapeutics. Understanding when CIN promotes or suppress anti-tumor immunity is therefore needed. However, the mechanism and initiators by which this adjustment occurs and the role that aneuploidy, CIN or specific karyotypes have in this transition are still in the dark. In order to understand how CIN drives tumor evolution, we need to know how CIN guide cells into different immunogenic responses. Identifying the genes that adjust the role of CIN and aneuploidy in immune evasion can therefore help us unravel the origins of malignant growth and in the future develop more appropriate therapeutic approaches. My project plan is set to find the genes that trigger and connect chromosome missegregation to the interferon-inflammatory response in cells suffering from CIN using an unbiased genome-wide CRISPR KO screen coupled to a suicide gene switch in human fibroblasts. The use of a suicide gene switch, normally used for cell-based therapy, allows separation of cells that have lost the inflammatory pathway while the screen, along with a next generation sequencing, will find the genes related to that loss. This screen will serve as a base to understand what underlies cancer immune evasion in chromosomally unstable cells. ver más
31/12/2024
UNIVERSITAIR MEDIS...
188K€
Perfil tecnológico estimado
Duración del proyecto: 25 meses Fecha Inicio: 2022-11-22
Fecha Fin: 2024-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-11-22
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021
Cerrada hace 3 años
Presupuesto El presupuesto total del proyecto asciende a 188K€
Líder del proyecto
ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5